Literature DB >> 19626596

The time course of drug effects.

Hesham S Al-Sallami1, Venkata V Pavan Kumar, Cornelia B Landersdorfer, Jurgen B Bulitta, Stephen B Duffull.   

Abstract

This review aims to introduce the concepts and principles underpinning the time course of drug effects. Models describing the time course of drug concentrations (pharmacokinetic models) and the ensuing concentration-effect (pharmacodynamics models) as well as the linked time-effect (pharmacokinetic-pharmacodynamic models) are introduced. Different types of drug time-effects models are discussed with examples which aim to explain the time course of onset, duration, and maximal effect that occurs from any given dosing schedule. These drug effects are also described in relation to disease progression models. Copyright (c) 2009 John Wiley & Sons, Ltd.

Mesh:

Substances:

Year:  2009        PMID: 19626596     DOI: 10.1002/pst.393

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.894


  8 in total

Review 1.  Interpreting population pharmacokinetic-pharmacodynamic analyses - a clinical viewpoint.

Authors:  Stephen B Duffull; Daniel F B Wright; Helen R Winter
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

Review 2.  Understanding the time course of pharmacological effect: a PKPD approach.

Authors:  Daniel F B Wright; Helen R Winter; Stephen B Duffull
Journal:  Br J Clin Pharmacol       Date:  2011-06       Impact factor: 4.335

3.  Mechanism-based model of parasite growth and dihydroartemisinin pharmacodynamics in murine malaria.

Authors:  Kashyap Patel; Kevin T Batty; Brioni R Moore; Peter L Gibbons; Jürgen B Bulitta; Carl M Kirkpatrick
Journal:  Antimicrob Agents Chemother       Date:  2012-11-12       Impact factor: 5.191

Review 4.  Modelling the time course of antimalarial parasite killing: a tour of animal and human models, translation and challenges.

Authors:  Kashyap Patel; Julie A Simpson; Kevin T Batty; Sophie Zaloumis; Carl M Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

5.  Modeling NSCLC progression: recent advances and opportunities available.

Authors:  Ahmed Abbas Suleiman; Lucia Nogova; Uwe Fuhr
Journal:  AAPS J       Date:  2013-02-13       Impact factor: 4.009

6.  Comparative pharmacokinetics and pharmacodynamics of urocortins 1, 2 and 3 in healthy sheep.

Authors:  K Patel; M T Rademaker; C M J Kirkpatrick; C J Charles; S Fisher; T G Yandle; A M Richards
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

7.  Improving pharmacokinetic-pharmacodynamic modeling to investigate anti-infective chemotherapy with application to the current generation of antimalarial drugs.

Authors:  Katherine Kay; Ian M Hastings
Journal:  PLoS Comput Biol       Date:  2013-07-18       Impact factor: 4.475

8.  Dose-Response Analysis of the Effect of Carbidopa-Levodopa Extended-Release Capsules (IPX066) in Levodopa-Naive Patients With Parkinson Disease.

Authors:  Zhongping Lily Mao; Nishit B Modi
Journal:  J Clin Pharmacol       Date:  2016-01-18       Impact factor: 3.126

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.